Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine

High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non-Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway

(2012) G. Levallet et al.   MOLECULAR CANCER THERAPEUTICS

Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel

(2011) Jing Gao et al.   BMC CANCER

Thymidine synthase, thymidine phosphorylase and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma

(2010) S Lee et al.   BRITISH JOURNAL OF CANCER

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

(2010) Jaffer A. Ajani et al.   JOURNAL OF CLINICAL ONCOLOGY

Paclitaxel chemotherapy for the treatment of gastric cancer

(2009) Junichi Sakamoto et al.   Gastric Cancer

Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. class III β-tubulin

(2009) Christos D. Katsetos et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer

(2009) Koichiro Saito et al.   LARYNGOSCOPE

Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer: meta-analysis of randomized clinical trials

(2008) Suzana Angélica Silva Lustosa et al.   Acta Cirurgica Brasileira

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer

(2008) H J Kang et al.   BRITISH JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

(2008) Wasaburo Koizumi et al.   LANCET ONCOLOGY

Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel

(2008) Koichi Azuma et al.   LUNG CANCER

Proteomic characterization of cytoskeletal and mitochondrial class III  -tubulin

(2008) L. Cicchillitti et al.   MOLECULAR CANCER THERAPEUTICS

Hypoxia induces class III beta-tubulin gene expression by HIF-1α binding to its 3' flanking region

(2007) Giuseppina Raspaglio et al.   GENE